- Home
- SPPP vs TNXP Comparison
SPPP vs TNXP Comparison
Compare SPPP & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPPP
- TNXP
- Stock Information
- Founded
- SPPP 2011
- TNXP 2007
- Country
- SPPP Canada
- TNXP United States
- Employees
- SPPP N/A
- TNXP N/A
- Industry
- SPPP
- TNXP Biotechnology: Pharmaceutical Preparations
- Sector
- SPPP
- TNXP Health Care
- Exchange
- SPPP NYSE
- TNXP Nasdaq
- Market Cap
- SPPP 140.9M
- TNXP 116.9M
- IPO Year
- SPPP N/A
- TNXP N/A
- Fundamental
- Price
- SPPP $9.51
- TNXP $15.71
- Analyst Decision
- SPPP
- TNXP Strong Buy
- Analyst Count
- SPPP 0
- TNXP 2
- Target Price
- SPPP N/A
- TNXP $585.00
- AVG Volume (30 Days)
- SPPP 183.3K
- TNXP 1.5M
- Earning Date
- SPPP 01-01-0001
- TNXP 05-12-2025
- Dividend Yield
- SPPP N/A
- TNXP N/A
- EPS Growth
- SPPP N/A
- TNXP N/A
- EPS
- SPPP N/A
- TNXP N/A
- Revenue
- SPPP N/A
- TNXP $10,094,000.00
- Revenue This Year
- SPPP N/A
- TNXP $12.17
- Revenue Next Year
- SPPP N/A
- TNXP $789.15
- P/E Ratio
- SPPP N/A
- TNXP N/A
- Revenue Growth
- SPPP N/A
- TNXP 29.94
- 52 Week Low
- SPPP $8.55
- TNXP $6.76
- 52 Week High
- SPPP $11.39
- TNXP $672.00
- Technical
- Relative Strength Index (RSI)
- SPPP 51.39
- TNXP 44.80
- Support Level
- SPPP $9.01
- TNXP $15.23
- Resistance Level
- SPPP $9.69
- TNXP $22.25
- Average True Range (ATR)
- SPPP 0.14
- TNXP 2.36
- MACD
- SPPP 0.02
- TNXP -0.54
- Stochastic Oscillator
- SPPP 58.25
- TNXP 16.54
About SPPP SPROTT PHYS PLATINUM & PALLADIUM
Sprott Physical Platinum & Palladium Tr invests and holds all of its assets in physical platinum and palladium bullion. The company seeks to provide a secure, convenient, and exchange-traded investment alternative for investors interested in holding physical platinum and palladium bullion without the inconvenience that is typical of a direct investment in physical bullion. The Trust invests mainly in long-term holdings of unencumbered, fully allocated, physical platinum and palladium bullion.
About TNXP Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.